增生疗法市场－全球产业规模、份额、趋势、机会和预测，按类型、应用、地区和竞争格局划分，2020-2030年预测

2024年全球增生疗法市场规模为12.8041亿美元，预计到2030年将以6.90%的复合年增长率增长至19.108亿美元。增生疗法，又称增殖疗法，是一种注射式再生医学治疗方法，旨在透过在韧带和肌腱薄弱部位诱导可控的发炎反应来刺激人体自身的癒合过程。此疗法通常使用高渗透压葡萄糖溶液来促进组织再生并强化结缔组织。全球增生疗法市场的成长主要受以下因素驱动：全球慢性肌肉骨骼疾病盛行率的不断上升，以及对非手术、微创疼痛管理治疗方案日益增长的需求。

主要市场驱动因素

主要市场挑战

主要市场趋势

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球增生疗法市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依类型（关节注射增生疗法、韧带增生疗法、肌腱重建增生疗法）
  • 依应用领域（医院、门诊中心、骨科中心、其他）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美增生疗法市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲增生疗法市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区增生疗法市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲增生疗法市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲增生疗法市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购（如有）
• 产品发布（如有）
• 最新进展

第十三章：全球增生疗法市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Pfizer Inc.
• Baxter International Inc.
• B. Braun AG
• Fresenius SE & Co. KGaA
• ICU Medical, Inc.
• Johnson & Johnson
• Arthex Inc.
• Aurobindo Pharma Limited
• Terumo Corporation
• Amphastar Pharmaceuticals, Inc.

第十六章：策略建议

第17章调查会社について・免责事项

The Global Prolotherapy Market, valued at USD 1280.41 Million in 2024, is projected to experience a CAGR of 6.90% to reach USD 1910.80 Million by 2030. Prolotherapy, or proliferative therapy, is an injection-based regenerative medical treatment designed to stimulate the body's natural healing processes by inducing a controlled inflammatory response at the site of weakened ligaments and tendons, typically utilizing hyperosmolar dextrose solutions to foster tissue regeneration and strengthen connective tissues. The global prolotherapy market's expansion is fundamentally driven by the escalating prevalence of chronic musculoskeletal disorders worldwide and the growing demand for non-surgical, minimally invasive treatment alternatives for pain management.

Key Market Drivers

The escalating global prevalence of musculoskeletal disorders and chronic pain represents a primary market driver for prolotherapy. These conditions significantly impact quality of life and impose substantial healthcare burdens worldwide. The widespread nature of these ailments creates a consistently large patient pool seeking effective and less invasive treatment options. According to the International Association for the Study of Pain, in July 2023, "Global Burden of Musculoskeletal Conditions", an estimated 1.71 billion people globally were in need of rehabilitation due to musculoskeletal conditions, highlighting the extensive demand for therapies addressing such widespread issues. As incidence rates continue to rise, the foundational need for treatments like prolotherapy becomes increasingly pronounced, directly stimulating market expansion by providing solutions for persistent pain and functional limitations.

Key Market Challenges

The limited availability of robust, high-quality clinical evidence poses a significant impediment to the expansion of the global prolotherapy market. This evidentiary gap directly impacts the confidence of healthcare providers in recommending prolotherapy as a primary treatment option. Without comprehensive, long-term studies demonstrating consistent efficacy and safety, medical professionals often hesitate to integrate such interventions into standard practice protocols, thereby constraining patient referrals and limiting overall adoption rates.

Furthermore, the absence of strong clinical evidence fuels persistent regulatory uncertainty and contributes to variable insurance reimbursement policies across regions. For instance, according to the American Society of Interventional Pain Physicians (ASIPP) 2024 guidelines, the evidence for intradiscal injections of Platelet-Rich Plasma (PRP) and Mesenchymal Stem Cells (MSCs) is categorized as Level III, and Level IV for other related joint injections, on a five-level scale where Level I represents the strongest evidence. This limited strength of evidence for related regenerative therapies leads insurers to hesitate in covering treatments lacking substantial proof of long-term effectiveness. Such financial barriers reduce patient access, thereby stifling market penetration and growth.

Key Market Trends

Two key trends are significantly shaping the global prolotherapy market. Technological enhancements in injection guidance are improving the precision and safety of prolotherapy procedures, thereby increasing both practitioner confidence and patient acceptance. The integration of advanced imaging modalities, such as ultrasound, provides real-time visualization during injections, allowing for more accurate targeting of damaged tissues and minimizing potential complications. According to the Society of Diagnostic Medical Sonography, March 2024, "Now Available: Revised Scope of Practice and Clinical Standards for the Diagnostic Medical Sonographer," twenty participating organizations collaborated to revise the Scope of Practice and Clinical Standards for Diagnostic Medical Sonographers, reflecting the rapid technological advancements and evolving role of sonography in interventional procedures. This emphasis on enhanced guidance supports the widespread adoption of more accurate delivery methods for regenerative treatments.

Key Market Players

• Pfizer Inc.
• Baxter International Inc.
• B. Braun AG
• Fresenius SE & Co. KGaA
• ICU Medical, Inc.
• Johnson & Johnson
• Arthex Inc.
• Aurobindo Pharma Limited
• Terumo Corporation
• Amphastar Pharmaceuticals, Inc.

Report Scope:

In this report, the Global Prolotherapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Prolotherapy Market, By Type:

• Joint Injection Prolotherapy
• Ligament Prolotherapy
• Tendon Reconstruction Prolotherapy

Prolotherapy Market, By Application:

• Hospitals
• Ambulatory Care Centers
• Orthopedic Centers
• Others

Prolotherapy Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Prolotherapy Market.

Available Customizations:

Global Prolotherapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Prolotherapy Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Joint Injection Prolotherapy, Ligament Prolotherapy, Tendon Reconstruction Prolotherapy)
  • 5.2.2. By Application (Hospitals, Ambulatory Care Centers, Orthopedic Centers, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Prolotherapy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Prolotherapy Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Prolotherapy Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Prolotherapy Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application

7. Europe Prolotherapy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Prolotherapy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
  • 7.3.2. France Prolotherapy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Prolotherapy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Prolotherapy Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Prolotherapy Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application

8. Asia Pacific Prolotherapy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Prolotherapy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
  • 8.3.2. India Prolotherapy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Prolotherapy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Prolotherapy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Prolotherapy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application

9. Middle East & Africa Prolotherapy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Prolotherapy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
  • 9.3.2. UAE Prolotherapy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
  • 9.3.3. South Africa Prolotherapy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application

10. South America Prolotherapy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Prolotherapy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
  • 10.3.2. Colombia Prolotherapy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
  • 10.3.3. Argentina Prolotherapy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Prolotherapy Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Pfizer Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Baxter International Inc.
• 15.3. B. Braun AG
• 15.4. Fresenius SE & Co. KGaA
• 15.5. ICU Medical, Inc.
• 15.6. Johnson & Johnson
• 15.7. Arthex Inc.
• 15.8. Aurobindo Pharma Limited
• 15.9. Terumo Corporation
• 15.10. Amphastar Pharmaceuticals, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer